0001363213-16-000063.txt : 20160308 0001363213-16-000063.hdr.sgml : 20160308 20160308110853 ACCESSION NUMBER: 0001363213-16-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160304 FILED AS OF DATE: 20160308 DATE AS OF CHANGE: 20160308 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161490697 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2016-03-04 0 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2016-03-04 4 M 0 17594.0 2.49 A 222846 D Common Stock 2016-03-04 4 S 0 17594.0 10.006 D 205252 D Common Stock 2016-03-07 4 M 0 2406.0 2.49 A 207658 D Common Stock 2016-03-07 4 S 0 2406.0 10.0 D 205252 D Non-Qualified Stock Option (right to buy) 2.49 2016-03-04 4 M 0 17594.0 0.0 D 2016-06-02 Common Stock 17594 521566 D Non-Qualified Stock Option (right to buy) 2.49 2016-03-07 4 M 0 2406.0 0.0 D 2016-06-02 Common Stock 2406 519160 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2014. Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 29, 2016. Granted under the Issuer's 2005 Equity Incentive Plan. Provided the reporting person remains employed by or acting as a consultant to the Company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10. /s/Friedhelm Blobel, Ph.D. 2016-03-08